Skip to main content

  • In conjunction with the American Association of Ophthalmic Oncologists and Pathologists

    Evolving Paradigms in the Practice of Ocular Oncology and Pathology

    Friday, Nov. 3
    Moscone Center, San Francisco, CA

    Program Directors

    Miguel A. Materin, MD and Claudia Maria Prospero Ponce, MD

    Mission Statement

    The 2023 Ocular Oncology and Pathology Subspecialty Day aims to provide up-to-date discussions and debates on the most relevant, interesting, and controversial topics regarding ocular pathology and tumors of the eye and ocular adnexa. These include diagnostic tips, imaging information, currently available pathologic and molecular biologic diagnostic techniques, therapies including laser, radiation, local and systemic chemotherapy, and novel emerging therapies. This Subspecialty day maintains the audience updated on the Global health trends (ie DEI) and aims to equalize care and knowledge throughout USA and other countries. Information provided can be applied to patients seen in most ophthalmology practices, such as those with ocular surface tumors in corneal practices, intraocular tumors in retina practices, and eyelid/orbital tumors in comprehensive and oculoplastic practices.

    Target Audience

    The intended target audience for this program is practicing ophthalmologists, ocular pathologists, ocular oncologists, residents in training, and fellows.

    Education Level

    Intermediate, Advanced

    Program Objectives

    Upon completion of this activity, participants should be able to:

    • Identify clinical and pathologic features of certain tumors, such as uveal melanoma, retinoblastoma, and lymphoma.
    • Recognize prognostic features and testing that predict recurrence and mortality.
    • Identify and manage treatment complications such as second tumors and metastasis.
    • Explain current therapeutic options, including new areas of individualized targeted therapy of certain ocular tumors.
    • Recognize advances in solid tissue and liquid biopsies and ocular pathology.
    • Describe the impact of big data and population studies on our understanding of ocular tumors.
    • Determine when a patient should be referred to an ocular oncology center and when to consult an ocular pathologist.
    • Recognize the value of Diversity, Equity and Inclusion in the practice of ophthalmic pathology and oncology